Robert W. Baird reissued their buy rating on shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) in a research report released on Tuesday morning. Robert W. Baird currently has a $30.00 price objective on the stock.
JNCE has been the topic of a number of other reports. Zacks Investment Research raised shares of Jounce Therapeutics from a hold rating to a buy rating and set a $13.00 price target on the stock in a research note on Friday, August 11th. Cowen and Company reaffirmed a buy rating on shares of Jounce Therapeutics in a research note on Friday, June 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $23.67.
Jounce Therapeutics (NASDAQ:JNCE) opened at 14.75 on Tuesday. The stock has a market capitalization of $474.27 million and a P/E ratio of 546.30. The firm’s 50-day moving average is $14.92 and its 200 day moving average is $20.42. Jounce Therapeutics has a 12-month low of $14.62 and a 12-month high of $24.79.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. The company had revenue of $20.29 million for the quarter, compared to analyst estimates of $19.94 million. During the same period last year, the company earned ($7.23) earnings per share. Equities analysts expect that Jounce Therapeutics will post ($0.62) EPS for the current year.
Several large investors have recently bought and sold shares of the company. Teachers Advisors LLC grew its stake in shares of Jounce Therapeutics by 26.4% during the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after purchasing an additional 2,347 shares during the period. Nationwide Fund Advisors grew its stake in shares of Jounce Therapeutics by 203.3% during the 2nd quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after purchasing an additional 8,007 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Jounce Therapeutics by 46.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 25,574 shares of the company’s stock worth $359,000 after buying an additional 8,063 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in shares of Jounce Therapeutics by 180.0% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 12,600 shares of the company’s stock worth $177,000 after buying an additional 8,100 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Jounce Therapeutics in the 1st quarter worth about $212,000. 43.50% of the stock is currently owned by institutional investors and hedge funds.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.